Cytochrome P450 in vitro reaction phenotyping: a re-evaluation of approaches used for P450 isoform identification.

@article{Lu2003CytochromePI,
  title={Cytochrome P450 in vitro reaction phenotyping: a re-evaluation of approaches used for P450 isoform identification.},
  author={Anthony Y. H. Lu and Regina W. Wang and Jiunn Huei Lin},
  journal={Drug metabolism and disposition: the biological fate of chemicals},
  year={2003},
  volume={31 4},
  pages={
          345-50
        }
}
Marker substrates, chemical inhibitors, and inhibitory antibodies are important tools for the identification of cytochrome P450 (P450) isoform responsible for the metabolism of therapeutic agents in vitro. In view of the versatile and nonspecific nature of P450 enzymes, many of the marker substrates and chemical inhibitors used for P450 in vitro reaction phenotyping are isoform selective but not specific. Recently, the use of marker substrate and chemical inhibitors in CYP2D6 in vitro reaction… Expand
Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity
The majority of marketed small-molecule drugs undergo metabolism by hepatic Cytochrome P450 (CYP) enzymes (Rendic 2002). Since these enzymes metabolize a structurally diverse number of drugs,Expand
Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: evaluation of an approach based on the in vitro substrate disappearance rate
TLDR
The results suggest that glibenclamide is mainly metabolized by CYP3A4, whereas lansoprazole is metabolizing by both CYP2C19 and CYP 3A4 in human liver microsomes. Expand
Antibodies as a Probe in Cytochrome P450 Research
TLDR
The inhibitory antibodies are uniquely suited for reaction phenotyping that helps to predict human pharmacokinetics for clinical drug-drug interaction potential in drug discovery and development and for implications in pharmacogenetics and human risk assessment. Expand
Cytochrome P450 reaction-phenotyping: an industrial perspective
TLDR
In vitro CYP reaction-phenotyping and the integration of data are focused on and relatively simple strategies enabling the design and prioritization of follow up clinical studies are discussed. Expand
Monoclonal Antibodies and Multifunctional Cytochrome P450: Drug Metabolism as Paradigm
TLDR
The unique and precise specificity and high inhibitory activity toward individual cytochrome P450s make the monoclonal antibodies extraordinary tools for identifying and quantifying the role of each P450 isoform in the metabolism of a drug or nondrug xenobiotic. Expand
Selectivity of 7-alkoxycoumarins as probe substrates for rat hepatic cytochrome P450 forms is influenced by the substitution pattern on the coumarin nucleus
TLDR
The findings suggest that the sensitivity of probe substrates for CYP forms may be limited by the occurrence of competing side reactions of the substrate, and that better probes may be derived by blocking the sites of these side reactions. Expand
In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis®, Trabectidin®), a novel marine anti-cancer drug
TLDR
Evidence that CYP3A4 has a major role in the metabolism of ET-743 in vitro with additional involvement of CYP2C9, 2C19, 2D6, and 2E1 is provided, providing evidence that pharmacokinetic data of clinical trials and prediction of drug-drug interactions could be important. Expand
Chapter 12 Cytochrome p450 (cyp) and udp-glucuronosyltransferase (ugt) enzymes: role in drug metabolism, polymorphism, and identification of their involvement in drug metabolism
Publisher Summary The biotransformation of drugs is divided into two categories—Phase I and Phase II metabolism. Phase I reactions include oxidation, reduction, hydrolysis, and hydration. MetabolicExpand
The Combination of Chemical and Antibody Inhibitors for Superior P450 3A Inhibition in Reaction Phenotyping Studies
TLDR
The combination of chemical plus antibody inhibitors is explored to find whether P450 3A could be selectively and completely inhibited by using both inhibitors simultaneously. Expand
Validation of (-)-N-3-benzyl-phenobarbital as a selective inhibitor of CYP2C19 in human liver microsomes.
TLDR
NBPB can be used as a potent and selective inhibitor to establish the relative contribution of CYP2C19 for in vitro reaction phenotyping studies and can also serve as a positive control inhibitor of CY P450 reversible inhibition when human liver microsomes are used as the enzyme source. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 49 REFERENCES
Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes.
TLDR
Nine chemical inhibitors were selected based on literature data and were examined for their specificity toward cytochrome P450-mediated reactions in human liver microsomes and troleandomycin proved to be the most specific for testosterone 6 beta-hydroxylation. Expand
Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in assessment of human drug metabolism.
  • Q. Mei, C. Tang, +6 authors M. Shou
  • Biology, Medicine
  • The Journal of pharmacology and experimental therapeutics
  • 1999
TLDR
The results demonstrate that inhibitory and immunoblotting mAb(3A 4a) can offer a precise and useful tool for quantitative identification of CYP3A4/5 in the metabolism of drugs in clinical use and drugs in development. Expand
Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes.
TLDR
The findings indicate that the 4-hydroxylation of tamoxifen is catalysed almost exclusively by CYPs 2D6, 2C9 and 3A4 in human liver microsomes, but the marked between-subject variation in the contribution of these isoforms underlines the need to study metabolic reactions in a sufficient number of livers that are characterised with respect to a range of cytochrome P450 activities. Expand
A monoclonal antibody inhibitory to human P450 2D6: a paradigm for use in combinatorial determination of individual P450 role in specific drug tissue metabolism.
TLDR
These studies demonstrate that inhibitory monoclonal antibodies offer a simple and precise method for assessing the quantitative role of each P450 in the metabolism of a P450 substrate in a tissue, which include drugs, carcinogens, mutagens, toxic chemicals and endobiotics. Expand
Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples.
TLDR
Omeprazole 5-hydroxylation and sulfoxidation activities were determined in liver microsomes of different humans whose levels of individual forms of cytochrome P450 (P450 or CYP) varied and contributions to these P450 enzymes depend on the compositions of CYP2C19 and CYP3A4 in liver. Expand
Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin.
TLDR
These studies indicate that the N-demethylation of S-mephenytoin by human liver microsomes is catalyzed primarily by CYP2B6. Expand
Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members.
TLDR
The hypothesis that the aldehyde E3179 is an intermediate in the oxidation of losartan and that this two-step reaction is catalyzed in human liver microsomes by members of the CYP3A and CYP2C subfamilies is supported. Expand
Integrated Cytochrome P450 Reaction Phenotyping: Attempting to Bridge the Gap Between cDNA-expressed Cytochromes P450 and Native Human Liver Microsomes
TLDR
The reaction phenotype of a drug is assigned by integrating all three data sets (r, % TNR, and % I), and the normalized rate for each rCYP is expressed as a percent of the TNR (% TNR). Expand
Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate.
TLDR
The model-predicted relative contributions of individual CYP isoforms to the net biotransformation rate were similar to, and correlated with the fractional decrement in human liver microsomal reaction rates by chemical inhibitors of the respective CYPs, provided the chemical inhibitors used were specific to their target CYPs. Expand
Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174.
TLDR
Evidence is provided that P 4503A4 (and possibly other P4503A enzymes) play a major role in the formation of an active metabolite EXP3174, which is anactive metabolite of losartan. Expand
...
1
2
3
4
5
...